Why the study?
Does the combination of thromboxane synthetase inhibitors with low doses of aspirin prevent arachidonate-induced platelet aggregation in vitro?
Does the combination of thromboxane synthetase inhibitors with low doses of aspirin prevent arachidonate-induced platelet aggregation in vitro?
Answers are grounded in this paper and cite their sources.
The combination of thromboxane synthetase inhibitors with low-dose aspirin may offer greater antithrombotic potential than either drug alone by preventing platelet aggregation while preserving prostacyclin synthesis.
Selective pharmacological inhibition of thromboxane A2 synthesis did not prevent arachidonate-induced aggregation of human platelets in vitro. Prevention was instead achieved by a combination of thromboxane A2 inhibitors with low concentrations of aspirin. The latter partially reduced the proaggregatory cyclooxygenase products that accumulated when thromboxane A2 synthesis was blocked. The aspirin concentrations did not affect per se either platelet aggregation or prostacyclin synthesis in cultured human endothelial cells. The combination of thromboxane synthetase inhibitors with low doses of aspirin may offer greater antithrombotic potential than either drug alone.
No takes yet. Share an insight, caveat, or question.
Bertelè et al. (1983) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: